IL23A and psoriasis: Stimulation of the innate TLR7/TLR8 toll‐like receptors with imiquimod (IMQ), a synthetic agonist is sufficient to trigger IL‐23‐mediated psoriasis‐like skin inflammation (van der Fits et al, 2009), and CD11c+ DCs are the principal source of IL‐23 in the IMQ‐induced psoriasis‐like skin lesions (Riol‐Blanco et al, 2014).